Literature DB >> 19212647

FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).

Yuriko Katoh1, Masaru Katoh.   

Abstract

FGFR2 gene at human chromosome 10q26 encodes FGFR2b and FGFR2c isoforms functioning as FGF receptors with distinct expression domain and ligand specificity. FGFR2 plays oncogenic and anti-oncogenic roles in a context-dependent manner. Single nucleotide polymorphisms (SNPs) within intron 2 of FGFR2 gene are associated with breast cancer through allelic FGFR2 upregulation. Missense mutations or copy number gains of FGFR2 gene occur in breast cancer and gastric cancer to activate FGFR2 signaling. Aberrant FGFR2 signaling activation induces proliferation and survival of tumor cells. The class switch from FGFR2b to FGFR2c occurs during progression of prostate cancer and bladder cancer because of spliceosome dysregulation. In addition, epidermal Fgfr2b knockout mice show increased sensitivity to chemical carcinogenesis partly due to the failure of Nfe2l2 (Nrf2)-mediated detoxification of reactive oxygen species (ROS). Loss of FGFR2b signaling induces epithelial-to-mesenchymal transition (EMT) and unruly ROS. FGFR2 signaling dysregulation due to the accumulation of epigenetic modifications and genetic alterations during chronic inflammation, smoking, increased caloric uptake, and decreased exercise leads to carcinogenesis. PD173074, SU5402, AZD2171, and Ki23057 are small-molecule FGFR inhibitors. Human antibody, peptide mimetic, RNA aptamer, siRNA, and synthetic microRNA (miRNA) are emerging technologies to be applied for cancer therapeutics targeted to FGFR2. Because novel sequence technology and peta-scale super-computer are opening up the sequence era following the genome era, personalized medicine prescribing targeted drugs based on germline and/or somatic genomic information is coming reality. Application of FGFR2 inhibitors for cancer treatment in patients with FGFR2 mutation or gene amplification is beneficial; however, that for cancer prevention in people with FGFR2 risk allele might be disadvantageous due to the impediment of a cytoprotective mechanism against oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19212647     DOI: 10.3892/ijmm_00000132

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  51 in total

1.  The influence of neural cell adhesion molecule isoform 140 on the metastasis of thyroid carcinoma.

Authors:  An-Hang Yang; Yat-Pang Chau; Chen-Hsen Lee; Jui-Yu Chen; Jun-Yi Chen; Chien-Chih Ke; Ren-Shyan Liu
Journal:  Clin Exp Metastasis       Date:  2012-09-27       Impact factor: 5.150

2.  miR-381-3p suppresses the proliferation of oral squamous cell carcinoma cells by directly targeting FGFR2.

Authors:  Xiao Yang; Huibing Ruan; Xi Hu; Anyi Cao; Li Song
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

3.  Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2.

Authors:  C B Garcia; C M Shaffer; M P Alfaro; A L Smith; J Sun; Z Zhao; P P Young; M N VanSaun; J E Eid
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

4.  Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.

Authors:  Z Timsah; Z Ahmed; C Ivan; J Berrout; M Gagea; Y Zhou; G N A Pena; X Hu; C Vallien; C V Kingsley; Y Lu; J F Hancock; J Liu; A B Gladden; G B Mills; G Lopez-Berestein; M-C Hung; A K Sood; M Bogdanov; J E Ladbury
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

5.  Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR.

Authors:  Lincoln Nadauld; John F Regan; Laura Miotke; Reet K Pai; Teri A Longacre; Shirley S Kwok; Serge Saxonov; James M Ford; Hanlee P Ji
Journal:  Transl Med (Sunnyvale)       Date:  2012

Review 6.  Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer.

Authors:  Masakazu Yashiro; Tasuku Matsuoka
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

Review 7.  Signaling mechanisms of the epithelial-mesenchymal transition.

Authors:  David M Gonzalez; Damian Medici
Journal:  Sci Signal       Date:  2014-09-23       Impact factor: 8.192

8.  Altered expression of fibroblast growth factor receptor 2 isoform IIIc: relevance to endometrioid adenocarcinoma carcinogenesis and histological differentiation.

Authors:  Wei-Xia Peng; Mitsuhiro Kudo; Takenori Fujii; Kiyoshi Teduka; Zenya Naito
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

Review 9.  Epigenetic control of epithelial-mesenchymal-transition in human cancer.

Authors:  Tobias Kiesslich; Martin Pichler; Daniel Neureiter
Journal:  Mol Clin Oncol       Date:  2012-09-25

10.  Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing.

Authors:  Abhijeet P Deshmukh; Suhas V Vasaikar; Katarzyna Tomczak; Shubham Tripathi; Petra den Hollander; Emre Arslan; Priyanka Chakraborty; Rama Soundararajan; Mohit Kumar Jolly; Kunal Rai; Herbert Levine; Sendurai A Mani
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.